Skip to content

INOmax 10095Recalls & reported problems

Mallinckrodt Manufacturing LLC · Evolve System Assembly US · Class 2

Adverse event reports
3
Deaths reported
0
Injuries reported
3
Recalls naming it
0

Summary

The FDA's MAUDE database contains 3 adverse event reports that list this exact device (DI 00810055280063), received between Mar 27, 2025 and Apr 21, 2025 — classified as 3 injuries.

The most frequently reported specific device problem is “Low Readings” (3 reports).

Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.

Reports received per month

Nov 2023: 0 reportsDec 2023: 0 reportsJan 2024: 0 reportsFeb 2024: 0 reportsMar 2024: 0 reportsApr 2024: 0 reportsMay 2024: 0 reportsJun 2024: 0 reportsJul 2024: 0 reportsAug 2024: 0 reportsSep 2024: 0 reportsOct 2024: 0 reportsNov 2024: 0 reportsDec 2024: 0 reportsJan 2025: 0 reportsFeb 2025: 0 reportsMar 2025: 1 reportsApr 2025: 2 reportsMay 2025: 0 reportsJun 2025: 0 reportsJul 2025: 0 reportsAug 2025: 0 reportsSep 2025: 0 reportsOct 2025: 0 reportsNov 2025: 0 reportsDec 2025: 0 reportsJan 2026: 0 reportsFeb 2026: 0 reportsMar 2026: 0 reportsApr 2026: 0 reportsMay 2026: 0 reportsJun 2026: 0 reportsJul 2026: 0 reportsAug 2026: 0 reportsSep 2026: 0 reportsOct 2026: 0 reports2024202520262
Last 36 months. The most recent month may be incomplete.

Most reported problems

Device problems

  • Low Readings3
  • Failure to Deliver1
  • Intermittent Communication Failure1

Patient problems

  • Low Blood Pressure/ Hypotension2
  • Low Oxygen Saturation2

Recent adverse event reports

The 3 most recent of 3 reports, in the reporter's own words as published by the FDA.

  • InjuryApr 21, 2025Low Readings; Low Readings

    THE CUSTOMER CONTACTED MALLINCKRODT TO REPORT THEY EXPERIENCED INJECTOR MODULE REVERSE FLOW - HIGH PRIORITY ALARM WITH THEIR INOMAX EVOLVE DS DEVICE WHILE A PATIENT WAS RECEIVING INHALED NITRIC OXIDE (NO) THERAPY. THE CUSTOMER REPORTED THE ADULT PATIENT WAS BEING TRANSITIONED FROM THE HAMILTON G5 VENTILATOR TO THE HAMILTON T1 VENTILATOR IN PREPARATION FOR INTRA-HOSPITAL TRANSPORT. THE CUSTOMER STATED INOMAX THERAPY WAS INITIATED ON (B)(6) 2025, IN CONJUNCTION WITH HAMILTON G5 VENTILATOR WITH A SET NO DOSE OF 20PPM. THE CUSTOMER STATED THAT THE EVOLVE DEVICE WAS FULLY OPERATIONAL WHEN USED IN CONJUNCTION WITH THE HAMILTON G5. HOWEVER, THE CUSTOMER REPORTED SOON AFTER THE PATIENT WAS PLACED ON THE HAMILTON T1 VENTILATOR WITH SETTINGS OF PC-AC, PRESSURE CONTROL OF 14, RESPIRATORY RATE OF 20, PEEP +12, INSPIRATORY TIME OF 0.8 SECONDS, FLOW TRIGGER OF 5 L/MIN, AND FIO2 OF 30%, THE EVOLVE DEVICE ALARMED FOR INJECTOR MODULE REVERSE FLOW. THE CUSTOMER REPORTED THE PATIENT'S OXYGEN SATURATION DECREASED FROM 95% TO 84% AND THE MAP (MEAN ARTERIAL PRESSURE) DECREASED FROM 63 MMHG TO 48 MMHG "IMMEDIATELY". THE CUSTOMER STATED AS SOON AS THE PATIENT DECOMPENSATED, THEY PLACED THE PATIENT BACK ON

    Patient problems: Low Blood Pressure/ Hypotension; Low Oxygen Saturation

    MAUDE report 21877708 ↗
  • InjuryApr 21, 2025Low Readings; Low Readings

    THE CUSTOMER CONTACTED MALLINCKRODT TO REPORT THEY EXPERIENCED AN INJECTOR MODULE REVERSE FLOW - HIGH PRIORITY ALARM WITH THEIR INOMAX EVOLVE DS DEVICE WHILE A PATIENT WAS RECEIVING INHALED NITRIC OXIDE (NO) THERAPY. THE PATIENT WAS INITIATED ON INOMAX ON (B)(6) 2025 WITH A SET DOSE OF 20PPM. THE PATIENT WAS VENTILATED USING A MAQUET SERVO-U VENTILATOR IN PC/SIMV MODE WITH A RR40, PC18, PS14, PEEP+7, FIO2 OF 50%. THE BASELINE O2 SATURATION WAS BETWEEN 95% AND 98% VIA PULSE OXIMETRY. THE RETURNED TIDAL VOLUME WAS CONSISTENTLY AT APPROXIMATELY 9ML. THE PATIENT WAS NOT BREATHING ABOVE THE VENTILATOR AT THE TIME. THE CUSTOMER REPORTED THAT WHEN THEY TRANSITIONED THE PATIENT FROM THE INOMAX DSIR PLUS DELIVERY SYSTEM TO THE INOMAX EVOLVE DS WHEN THE INJECTOR MODULE REVERSE FLOW - HIGH PRIORITY ALARM AND LOW NO - ALARM OCCURRED. DURING THIS TIME, THE PATIENT EXPERIENCED OXYGEN DESATURATION, AND THE PATIENT WAS PLACED BACK ONTO THE DSIR PLUS DEVICE THAT HAD REMAINED AT THE BEDSIDE. THE CUSTOMER REPORTED THE PATIENT'S OXYGEN SATURATION DECREASED FROM BASELINE TO A LOW OF 50% DURING THIS EPISODE. THE CUSTOMER REPORTED THE STAFF DID NOT BAG THE PATIENT; HOWEVER, INCREASED THE FIO2 ON THE VENT

    Patient problems: Low Oxygen Saturation

    MAUDE report 21877485 ↗
  • InjuryMar 27, 2025Failure to Deliver; Low Readings; Intermittent Communication Failure; Failure to Deliver; Low Readings; Intermittent Communication Failure

    THE CUSTOMER CONTACTED MALLINCKRODT TO REPORT THEY EXPERIENCED A PRIMARY DELIVERY FAILURE ALARM WITH THEIR INOMAX EVOLVE DS DEVICE WHILE A PATIENT WAS RECEIVING INHALED NITRIC OXIDE (NO) THERAPY. THE PATIENT WAS AN ADULT BEING VENTILATED WITH A HAMILTON G5 VENTILATOR WITH THE FOLLOWING VENTILATOR PARAMETERS: VC-CMV, RR 12BPM, VT 220ML, FIO2 40% AND PEEP +5 CM H2O. THE PATIENT WAS RECEIVING INOMAX FOR APPROXIMATELY 12 HOURS WITH A SET DOSE OF 10PPM. THE RESPIRATORY THERAPIST WAS CALLED INTO THE PATIENT'S ROOM FOR A LOW NO ALARM AND UPON ARRIVAL A PRIMARY DELIVERY FAILURE ALARM WAS PRESENT. THE CUSTOMER REPORTED THE PATIENT WAS HYPOTENSIVE WITH BLOOD PRESSURE MONITORED BY ARTERIAL LINE OF 70/40 WITH A MEAN ARTERIAL PRESSURE OF 40MMHG. THE RESPIRATORY THERAPIST REPORTED THEY WERE "UNSURE IF THE EINOBLENDER WOULD STILL WORK" DUE TO THE PRIMARY DELIVERY FAILURE ALARM AND LEFT TO RETRIEVE A REPLACEMENT INOMAX EVOLVE DS. THE CUSTOMER REPORTED THAT ANOTHER HEALTHCARE PROVIDER ARRIVED SHORTLY AFTER AND NOTED THE ALARM, AND THEN IMMEDIATELY ACTIVATED THE EINOBLENDER AT 10PPM AND BEGAN TO VENTILATE THE PATIENT USING THE EINOBLENDER AND A MANUAL RESUSCITATOR BAG. THE PATIENT RESPONDED QUICKLY

    Patient problems: Low Blood Pressure/ Hypotension

    MAUDE report 21710364 ↗

Other Apparatus, Nitric Oxide Delivery devices

All Apparatus, Nitric Oxide Delivery devices →

Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.